glp 1 drugs covered by medicaid MCT2D GLP-1 Weight Loss Drugs: Coverage

10.1007/s00404-022-06700-3

1 T2DM remains as one of the leading causes of disability and death worldwide mainly due to its long-term vascular complications

This requires frequently assessing and adapting treatment plans to align with patients changing health status

Secondary Research Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research

Points represent beta coefficients in Kg and error bars represent the 95% confidence intervals